NCT06894628 Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation
| NCT ID | NCT06894628 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Regina Elena Cancer Institute |
| Condition | Prostatic Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 103 participants |
| Start Date | 2024-11-04 |
| Primary Completion | 2027-11-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 103 participants in total. It began in 2024-11-04 with a primary completion date of 2027-11-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to validate the Decipher® genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5+ Gy/fraction). Validating the Decipher® genomic classifier based on the expression of 22 RNA genes in the prospective study "esSBRT"
Eligibility Criteria
Inclusion Criteria: * patients enrolled at IRE under the "esSBRT" protocol (meeting the criteria of the same); * patients who express written informed consent personally or through their legal representative/witness/curator/guardian/support administrator (participation in the ancillary study and data processing) Exclusion Criteria: * all exclusion criteria adopted for the "esSBRT" study.
Contact & Investigator
Giuseppe Sanguineti, Doctor
PRINCIPAL INVESTIGATOR
IRCCS National Cancer Institute
Frequently Asked Questions
Who can join the NCT06894628 clinical trial?
This trial is open to male participants only, studying Prostatic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06894628 currently recruiting?
Yes, NCT06894628 is actively recruiting participants. Contact the research team at giuseppe.sanguineti@ifo.it for enrollment information.
Where is the NCT06894628 trial being conducted?
This trial is being conducted at Roma, Italy.
Who is sponsoring the NCT06894628 clinical trial?
NCT06894628 is sponsored by Regina Elena Cancer Institute. The principal investigator is Giuseppe Sanguineti, Doctor at IRCCS National Cancer Institute. The trial plans to enroll 103 participants.